Wird geladen...

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice

Immunotherapy is gathering momentum as a primary therapy for cancer patients. However, monotherapies have limited efficacy in improving outcomes and benefit only a subset of patients. Combination therapies targeting multiple pathways can augment an immune response to improve survival further. Here,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Linch, Stefanie N., Kasiewicz, Melissa J., McNamara, Michael J., Hilgart-Martiszus, Ian F., Farhad, Mohammad, Redmond, William L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2016
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4725491/
https://ncbi.nlm.nih.gov/pubmed/26729864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1510518113
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!